Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. develops late clinical-stage biopharmaceutical programs for cardiometabolic and inflammatory diseases. Company news centers on clinical development of enobosarm, an oral selective androgen receptor modulator being studied with GLP-1 receptor agonist therapy to make weight reduction more selective for fat loss while preserving lean mass, physical function, and bone.
Recurring updates also cover sabizabulin, an oral microtubule disruptor being developed for chronic inflammation related to atherosclerotic cardiovascular disease. Veru’s announcements commonly include fiscal results, business updates, clinical-study progress, regulatory feedback, scientific presentations, and conference webcasts tied to its small-molecule pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, will host a conference call and audio webcast on May 11, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 Q2 financial results and provide a business update. Interested investors can access the call through the company's website or by dialing specified telephone numbers. Veru is focused on developing treatments for breast cancer and SARS-CoV-2, with ongoing clinical trials for its candidates, including enobosarm for metastatic breast cancer and sabizabulin for COVID-19. Sabizabulin has shown a statistically significant 51.6% reduction in deaths in a Phase 3 trial. The company plans to conduct further trials and has received Fast Track designation from the FDA for its COVID-19 treatment.
Veru Inc. (NASDAQ: VERU) has announced the sale of its ENTADFI® business to Blue Water Vaccines, Inc. for a total of $20 million, with potential additional earnings of up to $80 million based on sales milestones. The deal includes an upfront payment of $6 million and scheduled payments of $4 million in fiscal 2023 and $10 million in fiscal 2024. This move aims to provide Veru with the financial flexibility needed to further develop its drug candidates, namely enobosarm for metastatic breast cancer and sabizabulin for SARS-CoV-2 related complications, with Phase 3 data anticipated in 2024. The company is also advancing multiple studies focusing on infectious diseases and oncology.
Veru Inc. (NASDAQ: VERU) has announced a Purchasing Agreement with Afaxys Group Services, LLC (AGS) to supply its FC2 Female Condom® through AGS's Group Purchasing Organization. This agreement aims to provide affordable contraceptive options to approximately 31 million individuals relying on community health services. The FC2 Female Condom is FDA-approved and serves dual functions: preventing unintended pregnancies and reducing sexually transmitted infections, including HIV/AIDS. A preferred pricing model will ensure access for healthcare providers serving underrepresented populations. Dr. Mitchell Steiner, Veru's CEO, highlighted the agreement's role in enhancing accessibility to sexual and reproductive health services.
Veru Inc. (NASDAQ: VERU) has reported promising results from a preclinical study of sabizabulin, demonstrating its ability to inhibit the release and spread of the poxvirus, specifically the vaccinia virus. Conducted by researchers at the University of Rochester, the study showed significant dose-dependent inhibition of viral release and cell-to-cell spread at concentrations achievable with a 9mg daily oral dose. This breakthrough supports Veru's plans to expand sabizabulin's applications to combat smallpox and other related infections, especially during potential outbreaks. The company is set to meet with the FDA for a pre-Investigational New Drug meeting to discuss the Animal Rule regulatory pathway, indicating a strategic move towards clinical development for this promising antiviral.
Veru Inc. (NASDAQ: VERU) announced promising results from a preclinical study of sabizabulin, showing robust anti-inflammatory effects in a mouse model for influenza-induced Acute Respiratory Distress Syndrome (ARDS). The study demonstrated a significant reduction in inflammatory cells by 53% and critical cytokines like IL-6 by 74%. Following a positive Phase 3 COVID-19 clinical trial, Veru plans to initiate a Phase 3 study for hospitalized influenza patients at high risk for ARDS. The FDA granted an expedited meeting to discuss the confirmatory Phase 3 study for COVID-19. These developments highlight sabizabulin's potential as a broad antiviral and anti-inflammatory agent.